| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 62,137 | 54,301 | 52,078 | 135,586 |
| Short-term investments | 278,488 | 334,648 | 363,974 | 155,444 |
| Accounts receivable, net | 34,192 | 26,081 | 33,034 | 26,122 |
| Inventory | 28,651 | 25,753 | 22,107 | 18,872 |
| Prepaid expenses and other current assets | 26,622 | 26,133 | 23,609 | 24,656 |
| Total current assets | 430,090 | 466,916 | 494,802 | 360,680 |
| Property and equipment, net | 1,065 | 1,104 | 237 | 297 |
| Right-of-use asset | 2,936 | 3,049 | 3,158 | 3,262 |
| Intangible assets, net | 5,106 | 5,319 | 5,533 | 5,747 |
| Restricted cash | 601 | 522 | 671 | 527 |
| Other long-term assets | 2,518 | 3,286 | 2,473 | 2,220 |
| Total assets | 442,316 | 480,196 | 506,874 | 372,733 |
| Accounts payable | 12,299 | 13,947 | 13,631 | 15,982 |
| Accrued expenses and other current liabilities | 80,045 | 83,855 | 84,456 | 69,185 |
| Other current liability - lg chem | NaN | 0 | NaN | 40,000 |
| Lease liability | 676 | 650 | 624 | 510 |
| Deferred revenue | 48 | 194 | NaN | NaN |
| Deferred royalty obligation, current | 10,130 | 7,296 | 5,556 | 3,778 |
| Total current liabilities | 103,198 | 105,942 | 104,267 | 129,455 |
| Deferred royalty obligation | 98,339 | 100,886 | 103,409 | 106,014 |
| Lease liability, non-current | 3,163 | 3,342 | 3,515 | 3,681 |
| Derivative liability | NaN | 0 | NaN | NaN |
| Total liabilities | 204,700 | 210,170 | 211,191 | 239,150 |
| Series a convertible preferred stock, 0.001 par value 150,000 shares authorized 132,500 and 132500 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively. liquidation preference of 132,500 and 132,500 as of march 31, 2026, and december 31, 2025, respectively | 114,710 | 130,957 | 146,866 | 145,491 |
| Common stock, 0.001 par value 120,000,000 shares authorized 68,445,084 and 67,205,321 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 69 | 67 | 67 | 64 |
| Additional paid-in capital | 1,529,909 | 1,491,675 | 1,454,048 | 1,241,744 |
| Accumulated other comprehensive income (loss) | 444 | -796 | -926 | -2,248 |
| Accumulated deficit | -1,407,516 | -1,351,877 | -1,304,372 | -1,251,468 |
| Total stockholders equity | 122,906 | 139,069 | 148,817 | -11,908 |
| Total liabilities, convertible preferred stock and stockholders equity | 442,316 | 480,196 | 506,874 | 372,733 |
RHYTHM PHARMACEUTICALS, INC. (RYTM)
RHYTHM PHARMACEUTICALS, INC. (RYTM)